Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 09:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

Latest news
Date Title
<1m ago COMMERZBANK HOLDINGS (UK) LIMITED - Capital Reorganisation
<1m ago RESEARCH AND MARKETS : India PVC Pipes and Fittings Industry Outlook to 2019 - Expanding Irrigated Area and Housing Sector to Stimulate Growth
<1m ago MEDIA ADVISORY : Giant Tiger in Angus, ON Unveils New Modern Look
1m ago DIRECT LINE INSURANCE : DIRECTOR DEALINGS: Direct Line Managers Acquire Shares
1m ago KVH : Introduces Safety and Security Training Programs for Superyachts
2m ago SYNERGY HEALTHCARE : Pentwater Capital Management LP : - Form 8.3 - Synergy Health Plc
2m ago Prudential Home Team Realty Joins Berkshire Hathaway HomeServices Real Estate Brokerage Network
3m ago NGL ENERGY PARTNERS : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
3m ago HMT UK HER MAJESTY TREASURY : Government launches consultation on further housing market powers for Bank of England
3m ago STORA ENSO : invests in quality and cost-competitiveness of Imatra Mills in Finland
Latest news
Advertisement
Hot News 
CERAGON NETWORKS : Reports Third Quarter 2014 Financial Results
WESTERN GAS PARTNERS : Prices Public Offering of 7,500,000 Common Units
ABIOMED : Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year
ACCURAY : misses Street 1Q forecasts
PAREXEL : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
Most Read News
2h ago WORLD WRESTLING ENTERTAINMENT : WWE :® Reports 2014 Third Quarter Results
1d ago MEDASSETS : tops Street 3Q forecasts
1d ago GENERAL MOTORS' : Trademark Application for "GOODWRENCH" Filed
6h ago Volkswagen profit jumps on record Audi, Porsche sales
2h ago Lufthansa shares drop after 2015 profit guidance cut for second time
Most recommended articles
4m ago Tricky path ahead for Fed - CMC Markets
4m ago UK outlines new legal powers for Bank of England to regulate mortgages
5m agoDJCopper Drops on Stronger Dollar
6m agoDJU.S. Stocks Fall; Visa Boosts Dow
19m ago Power of 'France Inc' on display in Sanofi boardroom coup
Dynamic quotes  
ON
| OFF